New Delhi: Government data for the financial year 2023-2024 reveals that out of 1,06,150
drug samples tested, 2,988 were found to be of substandard quality, while 282 were identified
as spurious. Legal action was initiated in 604 cases related to the production, sale, and
distribution of these counterfeit medicines.
As part of an intensified campaign to combat substandard and fake drugs, the Central Drugs
Standard Control Organisation (CDSCO) has been conducting inspections. India, home to
approximately 10,500 pharmaceutical manufacturing units, has seen over 500 risk-based
inspections at various facilities.
“Non-compliant units were issued show-cause notices, and measures such as production
halts, license suspensions, and cancellations were implemented by the State Licensing
Authorities,” an official stated.
This crackdown, led by the Drug Controller General of India (DCGI), has resulted in the
closure of non-compliant companies. Industry expert Gupta emphasized the importance of
publishing a company-wise list of quality-assured drugs to enhance public confidence.
Menu
